These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 2438776)
1. In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine. Onetto N; Momparler RL; Momparler LF; Gyger M Semin Oncol; 1987 Jun; 14(2 Suppl 1):231-7. PubMed ID: 2438776 [No Abstract] [Full Text] [Related]
2. 5-aza-2'-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Momparler RL; Bouchard J; Onetto N; Rivard GE Leuk Res; 1984; 8(2):181-5. PubMed ID: 6201685 [TBL] [Abstract][Full Text] [Related]
3. Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia. Colly LP; Peters WG; Richel D; Arentsen-Honders MW; Starrenburg CW; Willemze R Semin Oncol; 1987 Jun; 14(2 Suppl 1):257-61. PubMed ID: 3035720 [TBL] [Abstract][Full Text] [Related]
4. In vivo development of cytosine arabinoside resistance in the BN acute myelocytic leukemia. Hagenbeek A; Martens AC; Colly LP Semin Oncol; 1987 Jun; 14(2 Suppl 1):202-6. PubMed ID: 3473677 [TBL] [Abstract][Full Text] [Related]
5. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. Beauséjour CM; Gagnon J; Primeau M; Momparler RL Biochem Biophys Res Commun; 2002 May; 293(5):1478-84. PubMed ID: 12054682 [TBL] [Abstract][Full Text] [Related]
6. High-dose cytosine arabinoside: advances in clinical pharmacology and therapeutic results. Woodruff RK; Wiley JS Aust N Z J Med; 1983 Dec; 13(6):561-3. PubMed ID: 6586146 [No Abstract] [Full Text] [Related]
7. Lack of cross-resistance between cytosine arabinoside and a new halogenated nucleoside analogue, 2-bromo-2'-deoxyadenosine in human acute myeloid leukaemia cells. Pemble LB; Lihou MG; Blakley RL; Jamieson GP; Smith PJ Cancer Chemother Pharmacol; 1987; 20(2):155-61. PubMed ID: 3499252 [TBL] [Abstract][Full Text] [Related]
8. Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Chabot GG; Bouchard J; Momparler RL Biochem Pharmacol; 1983 Apr; 32(7):1327-8. PubMed ID: 6189497 [No Abstract] [Full Text] [Related]
9. [Clinical use of cytosine arabinoside in childhood. II. Cytosine arabinoside in the prevention and therapy of leukemic meningosis]. Masi M; Paolucci P; Vivarelli F; Vecchi V Minerva Pediatr; 1975 Sep; 27(30):1624-31. PubMed ID: 1058332 [No Abstract] [Full Text] [Related]
10. Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia. Zittoun R; Marie JP; Zittoun J; Marquet J; Haanen C Semin Oncol; 1985 Jun; 12(2 Suppl 3):139-43. PubMed ID: 3859928 [No Abstract] [Full Text] [Related]
11. Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia. Abraham A; Devasia AJ; Varatharajan S; Karathedath S; Balasubramanian P; Mathews V Ann Hematol; 2015 May; 94(5):883-5. PubMed ID: 25391240 [No Abstract] [Full Text] [Related]
12. Sequential use of methotrexate, folinic acid, and cytosine arabinoside in the treatment of acute leukemia. Greenberg ML; Waxman S Eur J Cancer (1965); 1976 Aug; 12(8):617-23. PubMed ID: 1086210 [No Abstract] [Full Text] [Related]
13. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside]. Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385 [TBL] [Abstract][Full Text] [Related]
14. Cytidine deaminase and the development of resistance to arabinosyl cytosine. Steuart CD; Burke PJ Nat New Biol; 1971 Sep; 233(38):109-10. PubMed ID: 5285962 [No Abstract] [Full Text] [Related]
15. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Stegmann AP; Honders MW; Hagemeijer A; Hoebee B; Willemze R; Landegent JE Ann Hematol; 1995 Jul; 71(1):41-7. PubMed ID: 7543292 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of acute leukemias in the infancy with cytosine arabinoside]. Madon E; Baroncelli PG; Sacerdote A; Roberi PL Minerva Pediatr; 1971 Jun; 23(26):1125-9. PubMed ID: 5286310 [No Abstract] [Full Text] [Related]
17. Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy. Harris AL; Grahame-Smith DG; Potter CG; Bunch C Clin Sci (Lond); 1981 Feb; 60(2):191-8. PubMed ID: 6940687 [TBL] [Abstract][Full Text] [Related]
18. [Cytosine arabinoside in the therapy of acute leukoses]. Quaglino D; De Pasquale A; Curci G; Montero C; Piccinini L Minerva Med; 1971 Jun; 62(45):2271-82. PubMed ID: 5281484 [No Abstract] [Full Text] [Related]
19. High degree of resistance to 5-aza-2'-deoxycytidine in L1210 cells in vitro associated with almost complete loss of deoxycytidine kinase activity. Veselý J Neoplasma; 1987; 34(6):713-20. PubMed ID: 2448662 [TBL] [Abstract][Full Text] [Related]
20. [Clinical use of cytosine arabinoside in infancy. I. Cytosine arabinoside in the treatment of acute leukosis]. Masi M; Vivarelli F; Paolucci P; Vecchi V Minerva Pediatr; 1975 Sep; 27(28):1539-50. PubMed ID: 1101022 [No Abstract] [Full Text] [Related] [Next] [New Search]